AVITA Medical Inc当前公司基本面数据相对稳定,增长潜力很大。当前估值合理,在生物技术与医疗研究行业排名166/404位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价6.90。中期看,股价处于下降通道。近一个月,市场表现较差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
AVITA Medical Inc评分
相关信息
行业排名
166 / 404
全市场排名
293 / 4578
所属行业
生物技术与医疗研究
压力支撑
由于公司未披露,未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
6
位分析师
买入
评级
6.900
目标均价
+100.00%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
AVITA Medical Inc亮点
亮点风险
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
AVITA Medical, Inc. is a therapeutic acute wound care company. The Company’s technologies optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of its platform is the RECELL System for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin Cells, offering a solution for improved clinical outcomes at the point-of-care. In the United States, it also holds the exclusive rights to market, sell, and distribute Cohealyx, an AVITA Medical-branded collagen-based dermal matrix, and PermeaDerm, a biosynthetic wound matrix. Its technologies are designed to optimize skin restoration procedures, effectively accelerating patient healing and recovery. Its solutions improve the healing outcomes for patients with traumatic injuries and surgical repairs, addressing critical healing needs that arise from unpredictable and life-changing events.
公司代码RCEL
公司AVITA Medical Inc
CEOVance (Cary G)
网址https://www.avitamedical.com/
常见问题
AVITA Medical Inc(RCEL)的当前股价是多少?
AVITA Medical Inc(RCEL)的当前股价是 3.440。
AVITA Medical Inc的股票代码是什么?
AVITA Medical Inc的股票代码是RCEL。
AVITA Medical Inc股票的52周最高点是多少?
AVITA Medical Inc股票的52周最高点是14.160。
AVITA Medical Inc股票的52周最低点是多少?
AVITA Medical Inc股票的52周最低点是3.250。
AVITA Medical Inc的市值是多少?
AVITA Medical Inc的市值是524.48M。
AVITA Medical Inc的净利润是多少?
AVITA Medical Inc的净利润为-61.84M。
现在AVITA Medical Inc(RCEL)的股票是买入、持有还是卖出?
根据分析师评级,AVITA Medical Inc(RCEL)的总体评级为买入,目标价格为6.900。